Introduction: Inflammation is an established component of cardiovascular disease (CVD) and an underlying factor of several dermatologic conditions including rosacea, atopic dermatitis, and psoriasis. Identifying potential associations between these dermatologic and cardiovascular diseases can better inform holistic healthcare approaches. The objective of this study was to determine whether rosacea, psoriasis or atopic dermatitis are independent risk factors for CVD 1 year following diagnosis.
p = 0.2713), atopic dermatitis (OR 1.032, p = 0.8489), or psoriasis (OR 1.087, p = 0.4210). In univariate analysis, the INTRODUCTION Most dermatologic conditions are readily apparent to the physician taking care of the patient and can be indicators of inflammatory processes (i.e. atherosclerosis) occurring internally. Some authors discuss an association between psoriasis and cardiovascular disease (CVD) [1] [2] [3] [4] [5] [6] . Less clear associations exist between other dermatologic inflammatory conditions [atopic dermatitis (AD) and rosacea] and CVD. Similar to psoriasis, these conditions are (1) common and (2) may reflect underlying systemic inflammation. Following this same concept, these diseases are worth assessing for their independent contribution to CVD risk.
Adults diagnosed with or self-identifying to have AD are more likely to have risk factors associated with CVD including: being a current smoker (adjusted odds ratio (OR) 1.28, p\0.001), being a current heavy drinker (OR 1.58, p\0.001), having a lifetime prevalence of diabetes (OR 1.37, p\0.001), having a lifetime prevalence of high cholesterol (OR 1.29, p\0.001), or a lifetime prevalence of hypertension (OR 1.31, p\0.001) [7] . Using a Taiwanese nationwide database, a retrospective population-based study identified 20,323 patients with AD and 20,323 comorbidity-matched subjects (age C20 years).
After adjusting for age, sex, comorbidities, and medications used, the hazard ratio for experiencing ischemic stroke over a 4-year follow-up period was 1.33 (p = 0.001),
suggesting AD may be an independent risk factor of ischemic stroke [8] .
For rosacea, a case control study done by Duman et al. assessed the compared CVD risk factors for 60 rosacea patients and 50 age-and gender-matched controls. Rosacea patients were more likely than controls to have: high total cholesterol (199 mg/dL vs. 163, p\0.001), LDL (121 vs 101, p = 0.002), CRP levels (0.43 vs. 0.24 mg/L, p = 0.007), and a family history of premature CVD (p = 0.002) [9] . This study only assessed risk factors and did not look at cardiovascular endpoints. Also, the control subjects were only age and gender matched, so invariably there was residual confounding.
Nevertheless, patients with rosacea may be more likely to have CVD risk factors but this has not been shown to be an independent risk factor for CVD. In this study, we evaluate whether three dermatologic diseases that have inflammatory components contribute an independent risk for development of CVD outcomes at 1-year follow-up using a large commercial claims database.
METHODS
The data were analyzed as a case-control study with matching on covariates using propensity scores to quantify the association between the dermatologic diseases and CVD outcomes. The matching done with propensity scores used a Mahalanobis 1:1 algorithm using all the main effects from the regression except the dermatologic disease indicator variable [9] .
Setting and Participants
All variables come from the MarketScan TM Commercial Claims and Encounters database for 2005-2007 [10] . No new studies with human or animal subjects were performed by any of the authors. The people included in the analysis were in the range of 30-64 years old and had at least 1 year of follow-up data and 6 months of baseline data. We chose the lower age limit because CVD is less common in individuals younger than this age. We chose the upper age limit to minimize loss to follow-up that could occur from 65 year olds switching from commercial insurance to Medicare.
The dermatologic diseases group was composed of three arms: rosacea (ICD-9 695.3), psoriasis (ICD-9 696.1), or AD (ICD-9 691.XX, except for 691.0X). None of the arms have people with any of the other two skin conditions. They were all defined with diagnosis codes, having at least 2 entries each.
The dermatologic disease group was selected further using a washout period. We defined our washout period as at least a 180-day period after Those components were CVD, peripheral vascular disease (PVD), and old myocardial infarction (MI). We also examined the number of comorbid conditions, which could be as high as 14 (as opposed to the 17 conditions usually examined with Deyo-Charlson). In addition to the number of days spent in the hospital, we examined the total number of hospitalizations
for the year but did not include this in the regression in order to reduce multi-collinearity.
We also looked at the medication costs directly related to the skin conditions as defined in the washout period, for a total of 365 days post-treatment. In addition to summing the costs per person, we looked at the number of prescription drug refills related to these costs for that year. We further examined the total medical costs divided into yearly inpatient, outpatient, and medication costs.
Study Size
The sample size was determined by the exclusion criteria and the eventual propensity score selection. The control group originally was comprised of 20,000 people and many were not included because they did not match well to the dermatologic disease group. Given the large sample size, we did not perform a power analysis prior to the study to estimate the effect size we could detect.
Statistical Methods
The study was designed to examine the independent risk of CVD among the Table 1 ). We used a 365-day follow-up period for the exposure and control in order to standardize the results. Thus, variables such as cost and healthcare utilization will also be generalizable to other studies. The propensity scores were generated for the three dermatologic disease arms versus the control group, and certain people were selected from the randomly created control group using Mahalanobis matching [11] . All variables, except for the exposure variable, were included in the propensity score calculation. In order to look for a balanced propensity score set, we compared the covariates individually with effect sizes and with a global test designed by Hansen and Bowers [11, 12] . Continuous data were reported as mean (standard deviation) and categorical data were reported as n (%). Analyses were performed in SAS 9.4 (SAS Institute, Cary, NC, USA) and R [12] .
Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS

Participants
The sample sizes for the disease and control groups were arrived at separately. For the dermatologic disease group, we began with people having either outpatient or inpatient visits with ages inclusive between 30 and 64 years (n = 21,801,147). After excluding patients that lacked diagnosis criteria, sufficient wash-out period, at least 1 year of follow-up, and at least one outpatient record, there were 4263 remaining patients ( Fig. 1 ). For the control group, we began with a simple random sample of 20,000 people from the 2006 database. After excluding those of age less than 30 years or greater than 64 years, with less than 12 months of continuous enrollment, or with a diagnosis of the dermatologic diseases investigated, there were 14,162 patients. For health-related expenses, there were an average US$8508 of total costs (SD 16,069), Table 1 ). The propensity score matching reduced the Hansen and Bowers global test for balance between treatment and control populations from a Chi-square value of 1155 (p\0.0001) to 12.4 (p = 0.0528).
Logistic Regression Model
We considered first an effects modification model, and found that the overall test for the variable was insignificant (F = 3.5118, p = 0.3912), and we reported only the main effects model. The model was highly predictive of the outcome with an AUC value of 0.7935. None of the three dermatologic disease groups had statistically significant increased odds of experiencing a CVD event at one year compared to the control group, after controlling for all other covariates ( We suspect that the longer follow-up period in their study may explain the potential discrepancy with our findings.
In our study, patients with rosacea were not statistically more likely to have comorbidities or an independent risk for cardiovascular disease.
This corroborates recent findings of Thyssen et al. which also found patients with rosacea were not more likely to have an independent risk of CVD or an increase in CVD risk factors (high cholesterol, LDL, and CRP) and environmental habits (increased smoking and drinking) [24] . A Taiwanese study did find that rosacea was significantly associated with CV comorbidities including dyslipidemia, hypertension, and coronary artery disease, although it lacked adjustment for important CV risk factors such as smoking and alcohol abuse [25] .
Limitations
The large sample size gave our study power to find even small clinical effect size. There were several prominent potential confounders for which the database does not collect data, including obesity and smoking and drinking history. Consequently, we expect a degree of residual confounding that may bias our estimate upward from the null. The washout period can potentially select a population with lower severity because it looks for new treatment patients, but this may be balanced by the fact that they are at least being treated by prescription medications. The study had a short follow-up period of 1 year, but there was a cross-section of many patient ages. With younger patients, 1 year may be insufficent to detect an increased risk of CVD. We used a large commercial claims database that is applicable to a 
